Dabur India to Remain in Focus After USFDA Inspection Observations

Shares of $DABUR are likely to remain in focus today after the company disclosed that the US Food and Drug Administration (USFDA) identified certain deficiencies related to data integrity and maintenance during an inspection of its manufacturing facility in Silvassa, Dadra and Nagar Haveli. The company stated that it has submitted appropriate responses to the inspectional observations and continues to engage with the regulator. Dabur has maintained that the facility remains operational and is taking corrective and preventive actions to address the identified gaps, while investors will closely monitor further regulatory developments. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.